Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients With Debilitating Movement Disorder Tardive Dyskinesia
Teva宣布Deutetrabenazine在欧洲患有令人痛苦的运动障碍扑翼样动作障碍的患者中的长期疗效和安全性
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients With Debilitating Movement Disorder Tardive Dyskinesia
Teva宣布Deutetrabenazine在欧洲患有令人痛苦的运动障碍扑翼样动作障碍的患者中的长期疗效和安全性
使用浏览器的分享功能,分享给你的好友吧